In Brief: Vasomedical Inc.
This article was originally published in The Gray Sheet
Vasomedical Inc.: Results of a 50-patient study of Enhanced External Counterpulsation (EECP) technology -- "a non-surgical therapy intended to reduce or eliminate symptoms of patients suffering from chronic stable angina pectoris" -- show that all patients receiving the treatment reported a decrease in anginal symptoms, researchers report in the May issue of The American Journal of Cardiology. Investigators William Lawson, MD, et. al., State University of New York at Stony Brook, say EECP facilitates blood flow through coronary collatorals by aiding the development of new collatorals or by enhancing flow through existing collatorals. The study also reports that 95% of patients with blockage of one vessel, 90% of patients with dual vessel blockage and 43% with triple blockage, experienced improvement post-treatment...
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.